Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
暂无分享,去创建一个
Y. Lotan | S. Shariat | P. Karakiewicz | Q. Trinh | M. Moschini | M. Abufaraj | B. Pradère | V. Schuettfort | Y. Nasu | E. Compérat | H. Mostafaei | J. Teoh | R. Sari Motlagh | K. Mori | S. Katayama | P. Rajwa | A. Aydh | N. Grossmann | E. Laukhtina | F. Quhal | F. König | Martin Haydter | Richard K. Lee
[1] D. Hayes. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Steinberg,et al. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Siddiqui,et al. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer , 2020, Investigative and clinical urology.
[4] A. Drilon,et al. MET-dependent solid tumours — molecular diagnosis and targeted therapy , 2020, Nature Reviews Clinical Oncology.
[5] J. Witjes,et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.
[6] T. Kamoto,et al. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers , 2020, International journal of molecular sciences.
[7] E. Giovannetti,et al. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers , 2019, Critical reviews in clinical laboratory sciences.
[8] H. Grossman,et al. Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? , 2019, European urology oncology.
[9] T. Nakazawa,et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. , 2018, Lung cancer.
[10] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[11] S. Shariat,et al. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder , 2018, World Journal of Urology.
[12] Young Hak Kim,et al. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer , 2017, Oncotarget.
[13] T. Klatte,et al. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy , 2016, Clinical genitourinary cancer.
[14] A. Vickers,et al. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.
[15] L. Pavone,et al. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation , 2015, Biomedicines.
[16] Sanjay G. Patel,et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. , 2015, European urology.
[17] R. Thompson,et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[18] M. Babjuk,et al. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. , 2013, European urology.
[19] A. Kibel. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .
[20] R. Millikan,et al. Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder , 2010 .
[21] U. Capitanio,et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. , 2010, The Journal of urology.
[22] Y. Toiyama,et al. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients , 2009, International journal of cancer.
[23] H. Kanetake,et al. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. , 2009, Human pathology.
[24] C. Roehrborn,et al. Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer , 2008, Clinical Cancer Research.
[25] Masayuki Takahashi,et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. , 2007, Urology.
[26] Y. Lotan,et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness , 2007, Modern Pathology.
[27] Y. Lotan,et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. , 2006, European urology.
[28] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[29] Chung-Liang Ho,et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Kitazawa,et al. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Nakamura,et al. Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions , 1996, Cancer Chemotherapy and Pharmacology.